End-stage renal disease (ESRD), also known as kidney failure, refers to the total failure of the kidneys to function, which necessitates renal replacement therapies such as dialysis or kidney transplantation to maintain life. Dialysis is primarily of two types—hemodialysis and peritoneal dialysis. Hemodialysis requires the use of a dialysis machine and a catheter or vascular access to connect the patient’s bloodstream with the dialyzer of the machine for excreting waste and excess water from the body. On the other hand, peritoneal dialysis makes use of the inner lining of the abdominal cavity called the peritoneum as a natural filter to clean the blood. It is commonly employed for patients who are unable to undergo hemodialysis.
The global End-Stage Renal Disease Treatment Market is estimated to be valued at US$ 98.27 billion in 2024 and is expected to exhibit a CAGR of 5.2% over the forecast period 2024-2031.
Advancements in dialysis techniques including short daily and nocturnal hemodialysis are enabling patients to undergo dialysis at home, thereby proving highly convenient. Furthermore, technological developments pertaining to dialysis equipment such as sorbent-based hemodialysis are aimed at achieving dialysis without water and reducing the costs associated with conventional hemodialysis.
Key Takeaways
Key players operating in the End-Stage Renal Disease (ESRD) Treatment are Fresenius Medical Care, DaVita Inc., Baxter, B. Braun Melsungen AG, and Asahi Kasei Medical.
The market is witnessing significant growth opportunities due to increasing healthcare expenditures in developing nations and rising awareness regarding kidney diseases and their treatment options.
New product launches, mergers & acquisitions and technological advancements in the fields of regenerative medicines, bioengineered organs and artificial kidneys are expected to positively impact the market over the forecast period.
Market Drivers
Increasing prevalence of diabetes and hypertension: Diabetes and hypertension are among the major causes leading to the development of kidney diseases and subsequently, ESRD. According to estimates, over 37 million Americans currently suffer from diabetes while nearly half of the US adult population suffers from hypertension. This has significantly fueled the incidence of ESRD over the past decade.
Current challenges in End-Stage Renal Disease (ESRD) Treatment Market:
The end-stage renal disease treatment market faces several challenges. Firstly, the prevalence of chronic kidney diseases is increasing rapidly across the world. This has led to a surge in the number of patients requiring treatments like dialysis and kidney transplantation. However, there is a significant shortage of donated kidneys for transplantation. Secondly, ESRD treatments like dialysis are very costly. The lifelong medical costs of dialysis pose a serious financial burden, especially in developing countries. Affordability of treatment remains a major hurdle. Thirdly, lifestyle diseases like diabetes and hypertension which often lead to kidney failure continue to rise at an alarming rate. This is further straining the healthcare resources. Lastly, the outcomes of ESRD treatments have significant scope for improvement. More effective and targeted therapies are needed to enhance quality of life and survival rates for ESRD patients.
SWOT Analysis
Strength: Dialysis provides an effective means for filtrating toxins and excess fluids from blood of patients with failed kidneys. It helps in sustaining life until transplantation. Weakness: Dialysis is an invasive and time-consuming process imposing physical and mental strain. It doesn’t completely replicate kidney functions. Opportunity: Development of more user-friendly home dialysis devices and therapies can encourage self-care and reduce healthcare costs. Threats: Shortage of donated organs limits kidney transplantation output. Growing prevalence of lifestyle diseases pose risk of higher ESRD burden in future.
Geographical regions with highest market value currently include North America, Europe, and Japan due to large dialysis patient populations and high healthcare spending in these regions. The Asia Pacific region is expected to be the fastest growing market for ESRD treatments during the forecast period owing to rising incidence of kidney diseases, growing geriatric demography, improving access to healthcare facilities, and increasing focus of leading market players in developing countries.
What Are The Key Data Covered In This End-Stage Renal Disease Treatment Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the End-Stage Renal Disease Treatment’s growth between 2024 and 2031.
:- Accurate calculation of the size of the End-Stage Renal Disease Treatment and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- End-Stage Renal Disease Treatment Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of End-Stage Renal Disease Treatment vendors
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author - Alice Mutum
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights. LinkedIn